Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Placebo-Controlled, Randomized, Double-Blind Study of 2 Doses of Crofelemer for the Treatment of Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC)

NCT06904872 is registered in ClinicalTrials.gov with Napo Therapeutics, S.p.A. as lead sponsor.

NCT NCT06904872
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06904872 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Placebo-Controlled, Randomized, Double-Blind Study of 2 Doses of Crofelemer for the Treatment of Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC)
Lead sponsor
Napo Therapeutics, S.p.A.
Phase
Phase 2
Overall status
Recruiting
Start date
May 29, 2025
Completion date
March 31, 2027
Enrollment
18 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

functional gastrointestinal disorders, malabsorption syndromes, post-op complication, short bowel syndrome, short gut syndrome